(Q33825554)

29 July 2017

1 reference

title

Neurocysticercosis and acquired cerebral toxoplasmosis in children (English)

1 reference

29 July 2017

0 references

1 reference

cerebral toxoplasmosis

1 reference

Mitchell WG

1

1 reference

29 July 2017

1 December 1999

1 reference

Seminars in pediatric neurology

29 July 2017

1 reference

29 July 2017

6

1 reference

29 July 2017

4

1 reference

29 July 2017

267-277

1 reference

Neurocysticercosis in an Orthodox Jewish community in New York City

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Neurocysticercosis in a child with no history of travel outside the continental United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Neurocysticercosis among children in Chicago

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Intraparenchymal cerebral cysticercosis in children: a benign prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

High prevalence of serological markers of cysticercosis among epileptic Malagasy children

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Neurocysticercosis in children. Clinical experience in 122 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Acute cysticercal meningitis in children: response to praziquantel

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Profuse neurocysticercosis with minimal signs and a favorable outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Anterior cerebral artery territory infarction in neurocysticercosis: evaluation by MR angiography and in vivo proton MR spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Cerebrovascular complications of neurocysticercosis. Clinical and neuroimaging spectrum.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Validation of diagnostic criteria for solitary cerebral cysticercus granuloma in patients presenting with seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Differentiating solitary small cysticercus granulomas and tuberculomas in patients with epilepsy. Clinical and computerized tomographic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Intramedullary spinal cysticercosis: response to albendazole: case reports and review of literature

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Therapy of parenchymal brain cysticercosis with praziquantel.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Single-day praziquantel therapy for neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Cysticercosis and epilepsy: a critical review.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Field trial of the coproantigen-based diagnosis of Taenia solium taeniasis by enzyme-linked immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Neurocysticercosis among patients with cerebral gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Cerebral cysticercosis in children in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Soil Survival of Toxoplasma Oocysts in Kansas and Costa Rica *

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

[Acquired toxoplasmosis with cerebral involvement and subsequent hearing loss]

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Acquired toxoplasma encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Parasitic infections of the central nervous system in children. Part II: Disseminated infections

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Toxoplasmosis of the central nervous system in non-human immunodeficiency virus-infected children: case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Hemidystonia secondary to acquired toxoplasmosis in a non-immunodeficient patient

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Extrapyramidal disorder secondary to cytomegalovirus infection and toxoplasmosis after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Choreoathetosis in acquired immune deficiency syndrome patients with cerebral toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

An unusual CT presentation of congenital cerebral toxoplasmosis in an 8 month-old boy with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Toxoplasmosis. Problems in diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Parasitic infections of the central nervous system in children. Part I: Congenital infections and meningoencephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Limited value of PCR for detection of Toxoplasma gondii in blood from human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Use of a monoclonal antibody and a DNA probe for diagnosing acute toxoplasmosis in ambiguous cases

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Management of intracerebral lesions in patients with HIV: a retrospective study with discussion of diagnostic problems

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Treatment regimens for patients with toxoplasmic encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

Opportunistic infections occurring during highly active antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9091%2899%2980025-4

7 January 2021

10.1016/S1071-9091(99)80025-4

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10649835